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Abstract
Introduction: We investigated the clinical outcome and the toxicity of trimodal therapy of malignant pleural
mesothelioma (MPM) treated with neoadjuvant chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant
intensity-modulated radiotherapy (IMRT).
Methods: Chemotherapy regimens included Cisplatin/Pemetrexed, Carboplatin/Pemetrexed and Cisplatin/
Gemcitabine, followed by EPP. 62 patients completed the adjuvant radiotherapy. IMRT was carried out in
two techniques, either step&shoot or helical tomotherapy. Median target dose was 48 Gy to 54 Gy. Toxicity
was scored with the Common Terminology Criteria (CTC) for Adverse Events. We used Kaplan-Meier method
to estimate actuarial rate of locoregional control (LRC), distant control (DC) and overall survival (OS), measured
from the date of surgery. Rates were compared using the logrank test. For multivariate analysis the Cox
proportional hazard model was used.
Results: The median OS, LRC and DC times were 20.4, 31.4 and 21.4 months. The 1-, 2-, 3-year OS rates were 63, 42,
28 %, the LRC rates were 81, 60, 40 %, and the DC rates were 62, 48, 41 %. We observed no CTC grade 4 or grade 5
toxicity. Step&shoot and helical tomotherapy were equivalent both in dosimetric characteristics and clinical outcome.
Biphasic tumor histology was associated with worse clinical outcome compared to epitheloid histology.
Conclusions: Mature clinical results of trimodal treatment for MPM were presented. They indicate that hemithoracic
radiotherapy after EPP can be safely administered by either step&shoot IMRT and tomotherapy. However, the optimal
prospective patient selection for this aggressive trimodal therapy approach remains unclear. This study can serve as a
benchmark for current and future therapy concepts for MPM.
Keywords: Malignant pleural mesothelioma, Trimodal therapy, Intensity modulated radiation therapy, Extrapleural
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Introduction
Malignant pleural mesothelioma (MPM) is an aggressive
disease with a poor prognosis, currently treated with dif-
ferent combinations of chemotherapy, surgery and radio-
therapy. For each single treatment modality, significant
improvements have been achieved over the last years.
With respect to chemotherapy regimens, Pemetrexed
combined with Cisplatin has been established [1]; in sur-
gery approaches, extrapleural pneumonectomy (EPP)
and pleurectomy/decortication (P/D) have been technic-
ally advanced resulting in tolerable toxicity [2]; moreover
the introduction of intensity-modulated radiotherapy
(IMRT) allows to conform the high dose area tightly to
the target volume and spare adjacent organs at risk [3].
However, despite these individual advancements the
optimal combination and treatment strategy for each
individual patient still remains unclear. Randomized
clinical trials have been difficult to organize due to the
rareness of the disease, patients presenting very differ-
ently at the time of diagnosis in terms of tumor spread,
histology and general performance status, and different
technical possibilities and experiences at different clin-
ical centers. Therefore, evaluations of the clinical out-
come of cohorts treated systematically by a certain
regimen are relevant to assess its potential and also the
associated risks for the patients.
In this work, we assessed and analyzed the clinical
outcome of consecutive MPM patients treated in Heidel-
berg, Germany, by hemithoracic intensity-modulated




All MPM patients that completed adjuvant radiotherapy
at the Heidelberg University Hospital after chemother-
apy and EPP between 2003 and 2010 were included in
this study. This required adequate recovery from sur-
gery. To be eligible for EPP, the patients were required
to have localized disease (maximum cT4N2M0), epithe-
loid or biphasic tumor histology, and a sufficient general
performance status. This study was approved by the in-
dependent ethics committee of the medical faculty of
the University of Heidelberg.
Chemotherapy
All patients received neoadjuvant chemotherapy prior to
surgery, consisting of either Cisplatin/Pemetrexed, Car-
boplatin/Pemetrexed or Cisplatin/Gemcitabine.
Extrapleural pneumonectomy (EPP)
EPP included the removal of the complete afflicted lung
together with the parietal pleura, pericardium and dia-
phragm. It was performed via an extended S-shaped
anterolateral thoracotomy incision in the sixth intercostal
space. Sites of prior open biopsy, thoracoscopy incisions,
or chest tube tracks were excised separately. After resec-
tion, the diaphragm was replaced by a Monofilament Poly-
propylene mesh (Bard Mesh; Davol, Inc, Cranston, RI), and
the pericardium was reconstructed with a xenopericard
patch (Supple Peri-Guard; Synovis Surgical Innovations, St
Paul, MN). In all patients undergoing EPP, a systematic
mediastinal lymph node dissection was performed.
Radiotherapy
Immobilization
During the acquisition of the contrast-enhanced com-
puted tomography (CT) scan for treatment planning
(and also later for irradiation), patients were immobi-
lized by a vacuum body mattress and a Scotch-cast head
mask, with the arms above the head on a resting plate.
The surgical incisions were marked by thin metal wires
during the planning CT scan.
Segmentation
As planning target volume (PTV), the complete ipsilat-
eral thoracic cavity was segmented from lung apex to
insertion of the diaphragm, including the ribs, the recon-
structed pericardium and diaphragm, and extending up
to the skin surface along the surgical incisions, with a
safety margin of 5 mm which could be reduced at dir-
ectly adjacent organs at risk. It was also made sure that
all internal metal clips from surgery were included in the
target volume. The contralateral lung, heart, liver,
esophagus, spinal cord, and kidneys were segmented as
organs at risk.
IMRT planning
The treatment was performed either as step&shoot
IMRT or helical tomotherapy IMRT. For step&shoot
IMRT, treatment planning was performed using Konrad
(Siemens, Erlangen, Germany). We placed 9–12 copla-
nar, non-equidistant beams in order to achieve optimal
target coverage and sparing of the contralateral lung. For
helical tomotherapy, we used the Tomotherapy planning
system (Accuray, Sunnyvale, CA, USA). A field width of
2.5 cm was chosen. An example plan used for step-and-
shoot IMRT treatment showing both segmentation and
the resulting dose distribution is shown in Fig. 1.
IMRT delivery
Step&shoot IMRT was delivered by Siemens Primus and
Siemens Artiste linear accelerators (Siemens, Erlangen,
Germany) at 6 MV with regular image guidance (at least
once per week) by an in-room CT scanner (Siemens
Primatom, Erlangen, Germany). Helical tomotherapy was
delivered by a Tomotherapy Hi-Art system (Accuray,
Sunnyvale, CA, USA) at 6 MV, using built-in image
Thieke et al. Radiation Oncology  (2015) 10:267 Page 2 of 10
guidance acquired at 3 MV. Median target dose was 48 to
54 Gy in 2 Gy fractions.
Follow-up
Regular follow up visits were performed at our institu-
tion or the referring center. At our institution, patients
were scheduled for follow up visits 6 weeks after end of
radiotherapy and then every 3 months for the first
2 years, every 6 months for the three following years and
annually thereafter. Each follow-up visit included a pa-
tient interview, clinical examination and computed tom-
ography (CT) of the chest. In case of evidence for
locoregional recurrence or distant spread, additional
tests or imaging studies were performed to confirm or
exclude disease progression at the discretion of the treat-
ing physician. Missing data were completed by calling
the patient and/or the treating physician.
Toxicity was scored with the Common Terminology
Criteria (CTC) for Adverse Events version 4.0. Locore-
gional failure was defined as tumor relapse within the
treated ipsilateral hemithorax. Distant control was
defined as absence of tumor relapse outside the treated
ipsilateral hemithorax. In patients without assessment of
locoregional control/distant spread at the time of death,
the timepoint of the last locoregional control/distant
spread status was used for calculation.
Statistical analysis
The Kaplan-Meier method was used to estimate actuar-
ial rates of locoregional control (LRC), distant control
(DC), and overall survival (OS). Subgroups were com-
pared using the logrank test. The Cox proportional haz-
ard model was used for multivariate analysis. A p-value
of ≤ 0.05 was considered significant. Survival times were
calculated from the date of EPP surgery. Data were ana-
lysed using Statistica 6.0 (Statsoft, Tulsa, OK, USA).
Results
Patient characteristics
Between 2003 and 2010, 62 patients (pts) completed post-
operative radiotherapy after EPP in a trimodal treatment
setting in our institution. The patient characteristics are
Fig. 1 Structure definition and dose distribution for one MPM patient (Step & Shoot IMRT). In the coronar projection (a), the inclusion of the EPP
incisions into the target volume are marked by white arrows. The sagittal projection (b) shows the caudal extension of the target volume with
sparing of the liver and the kidney. In the two transverse slices the sparing of the heart (c) and again liver and kidney (d) can be seen
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outlined in Table 1. The most common postoperative
tumor staging was ypT3N0M0 (with 41 pts T3 and
43 pts N0), but also T2 (7 pts), T4 (4 pts), N1 (7 pts)
and N2 (6 pts) stages occurred.
Treatment characteristics
All patients received neoadjuvant chemotherapy. Regi-
mens used were Cisplatin/Pemetrexed (30 pts, 48.4 %),
Carboplatin/Pemetrexed (23 pts, 37.1 %) and Cisplatin/
Gemcitabine (9 pts, 14.5 %). Mostly 3 or 4 cycles of
chemotherapy were given; 5 patients received 6 cycles
and 1 patient received 7 cycles. The EPP surgery was
carried out mainly at the Thoracic Hospital at the Uni-
versity Clinic Heidelberg (58 pts, 82.9 %), but also in
other hospitals (12 pts, 17.1 %). The median interval be-
tween the date of diagnosis and date of EPP surgery was
4.4 months. The median interval between surgery and
start of radiotherapy was 8.4 weeks (range, 1.3–
46.1 weeks).
We started intensity-modulated radiotherapy for MPM
in 2003 with step & shoot technique. From 2006 on,
helical tomotherapy was used as an additional IMRT
technique. The first patients received median doses of
48Gy (2 pts, 3.2 %) and 50Gy (16 pts, 25.8 %) to the tar-
get volume in 2 Gy fractions. Later, the median target
dose was increased to 54Gy (44 pts, 71.0 %). In total, 41
pts (66.1 %) were treated with step&shoot and 21 pts
(33.9 %) with helical tomotherapy IMRT.
Dosimetric comparison of step&shoot and helical
tomotherapy IMRT
Several key dosimetric parameters were extracted from
the treatment planning systems to characterize the treat-
ment. They are listed in Table 2, including the standard
deviation (SD). The parameters are listed separately for
step&shoot-IMRT and helical tomotherapy as well as
combined for all patients. The mean target dose is a lit-
tle lower for step&shoot, since some of these patients
were planned to a median target dose of 48–50Gy,
whereas all tomotherapy patients were planned to a me-
dian target dose of 54Gy. The target dose coverage and
homogeneity is slightly better for helical tomotherapy,
with doses to some organs at risk (liver for right-sided
MPM, heart) also slightly higher. Especially the contra-
lateral lung could be spared very effectively with a mean
lung dose (MLD) of (7.6 ± 2.2) Gy, a V5Gy of (66.2 ±
23.0) % and a V20Gy of (1.7 ± 1.9) % for step&shoot-
IMRT and a MLD of (7.0 ± 1.2) Gy, a V5Gy of (71.5 ±
18.6) % and a V20Gy of (0.7 ± 1.3) % for helical
tomotherapy, respectively.
Table 1 Patient characteristics





Male 52 (83.9 %)
Female 10 (16.1 %)
Tumor location
Left 27 (43.5 %)
Right 35 (56.5 %)
Histology
Epitheloid 44 (70.9 %)
Biphasic 18 (29.1 %)
Table 2 Dosimetric parameters of the treatment plans
Step & Shoot Helical
Tomotherapy
All Patients








Mean Dose [Gy] 52.1 ± 2.3 53.5 ± 0.5 52.6 ± 2.0
Standard Deviation [Gy] 3.5 ± 1.5 2.4 ± 1.2 3.1 ± 1.5
V95% [%] 85.3 ± 5.3 92.3 ± 5.2 87.6 ± 6.2
V90% [%] 93.3 ± 3.8 94.2 ± 3.9 94.2 ± 3.9
Contralateral Lung
Mean Lung Dose [Gy] 7.6 ± 2.2 7.0 ± 1.2 7.4 ± 2.0
V5Gy [%] 66.2 ± 23.0 71.5 ± 18.6 67.9 ± 21.6
V20Gy [%] 1.7 ± 1.9 0.7 ± 1.3 1.4 ± 1.8
Liver (right-sided MPM)
Mean Dose [Gy] 21.9 ± 3.9 26.4 ± 3.8 23.4 ± 4.4
V30Gy [%] 24.7 ± 8.3 33.5 ± 7.8 27.5 ± 9.0
Liver (left-sided MPM)
Mean Dose [Gy] 9.1 ± 2.3 10.4 ± 1.5 9.6 ± 2.1
V30Gy [%] 2.0 ± 2.5 2.5 ± 2.7 2.2 ± 2.5
Heart
V45Gy [%] 7.3 ± 7.5 12.4 ± 6.1 9.0 ± 7.4
Ipsilateral kidney
Mean Dose [Gy] 9.9 ± 5.1 9.3 ± 2.5 9.7 ± 4.4
V15Gy [%] 23.4 ± 23.2 16.5 ± 13.0 21.0 ± 20.4
Contralateral kidney
Mean Dose [Gy] 3.1 ± 1.6 4.5 ± 1.5 3.6 ± 1.7
V15Gy [%] 0.1 ± 0.2 0.3 ± 0.6 0.2 ± 0.4
Spinal Cord
Maximum Dose [Gy] 36.0 ± 5.7 37.3 ± 5.3 36.4 ± 5.5
Esophagus
V55Gy [%] 0.9 ± 1.7 2.2 ± 2.4 1.4 ± 2.1
SD standard deviation, PTV planning target volume
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Toxicity of radiotherapy
Most common side effects were mild nausea and skin
erythema CTC grade 1–2. Many patients reported
fatigue during radiation treatment which improved after
completion of treatment. One patient developed symp-
tomatic anaemia during therapy, requiring the transfu-
sion of erythrocyte concentrates, but recovered well.
One patient showed radiological signs of pneumonitis in
the CT scan after radiotherapy, but was clinically asymp-
tomatic and needed no intervention (pneumonitis CTC
grade 1). One patient (treated with step&shoot IMRT,
MLD 10.7 Gy, V5Gy 92 %, V20Gy 5 %) developed clinic-
ally symptomatic radiation pneumonitis, which resolved
completely after treatment with prednisolone (CTC
grade 3). We observed no CTC grade 4 or grade 5
adverse effects of the irradiation.
Overall survival, locoregional control, distant control
The median follow-up time was 17.0 months (range,
2.4–111.9 months). Only 6 patients were still alive at the
time of analysis, with a median follow-up time of
60.6 months (range, 8.9–111.9 months). The data point
at 8.9 months was censored because the patient was lost
to follow-up, the other patients alive at the time of ana-
lysis had a follow-up time of at least 40 months.
The median overall survival (OS) for all 62 pts was
20.4 months. The OS after 1 year, 2 years and 3 years
was 63 % (SD 6 %), 42 % (SD 6 %) and 28 % (SD 6 %),
respectively. Median locoregional control (LRC) was
31.4 months. LRC after 1 year, 2 years and 3 years was
81 % (SD 6 %), 60 % (SD 9 %) and 40 % (SD 11 %), re-
spectively. Median distant control (DC) was 21.4 months.
DC after 1 year, 2 years and 3 years was 62 % (SD 7 %),
48 % (SD 8 %) and 41 % (SD 10 %), respectively.
The Kaplan-Meier curves for OS, LRC and DC are
shown in Fig. 2.
Factors associated with survival
Multivariate analysis showed that with respect to OS
among all the variables tested, the male gender
tended to result in worse prognosis although not
reaching significance (Hazard Ratio (HR) 1.7; 95 %
Confidence Interval (CI95) 0.7–4.9; p = 0.2). The only
two significant variables were the postoperative
Fig. 2 Kaplan-Meier curves for all patients. a Overall survival, b locoregional control and c distant control
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resection status R (per higher status HR 3.9; CI95
1.3–12.2; p = 0.01 and biphasic histology (HR 2.2;
CI95 1.2–5. 4; p = 0.03). With respect to locoregional
control, no variable tested reached significance in
multivariate analysis. However higher R status (HR
3.2; CI95 0.45–23.5; p = 0.2) and biphasic histology
(HR = 3.4; CI95 0.77–14. 9; p = 0.1) tended to result
in reduced local control. With respect to distant con-
trol, both higher R Status (HR 10.9; CI95 1.3–76. 2;
p = 0.02) and biphasic histology (HR 7.4; CI95 2.2–
25.4; p = 0.003) were significantly associated with
worse outcome. Other variables including the IMRT
technique (step&shoot vs. helical tomotherapy), dose
distributions such as target mean dose, target cover-
age, lung dose, clinical factors such as lymph node in-
volvement (N status), and patient factors such as age
had no influence on OS, LRC and DC. Kaplan-Meier
curves illustrating the equivalence of irradiation tech-
niques are depicted in Fig. 3 and the influence of the
histology is depicted in Fig. 4.
Discussion
In this work we present the long-term clinical outcome
of trimodal therapy of MPM consisting of neoadjuvant
chemotherapy, EPP and adjuvant hemithoracic IMRT
from a single institution. To our knowledge, our cohort
of 62 consecutive patients is one of the largest with the
longest follow-up times reported in the literature. The
median OS, LRC and DC were 20.4, 31.4 and
21.4 months. The actuarial 1-, 2-, and 3-year OS was 63,
42, 28 %, the LRC 81, 60, 40 %, and the DC was 62, 48,
41 %. No CTC grade 4 or grade 5 toxicity was observed.
A cohort of 86 MPM patients treated with IMRT after
EPP (57/86 without chemotherapy) were recently ana-
lyzed by Gomez et al. [4], who reported excellent locore-
gional control rates. Compared to these results, we
observed longer median OS (20.4 vs. 14.7 months) with
slightly better OS rates after 1 and 2 years (63 % vs.
55 % and 42 % vs. 32 %). Our locoregional control rates
after 1 and 2 years were slightly worse (81 % vs. 88 %
and 60 % vs. 71 %), but distant control rates after 1 and
Fig. 3 Kaplan-Meier curves separated for type of radiation treatment. Step&shoot-IMRT (“IMRT”) vs. helical tomotherapy-IMRT (“Tomo”) shows no
significant difference regarding a overall survival, b locoregional control and c distant control
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2 years slightly better (62 % vs. 55 % and 48 % vs. 40 %).
The dosimetric parameters of the radiotherapy were
roughly equivalent. The chemotherapy might have
caused the differences in DC and OS. This is consistent
with other reports where trimodal treatment of MPM
led to survival times of 20 months or more [5, 6]. We
have summarized the treatment characteristics, survival
times and acute lung toxicity of several reports in a table
that is accompanying this paper as an additional file (see
“Additional file 1”).
As reference time point from which the survival
times were measured, we chose the date of surgery,
as in [4, 7, 8]. This has to be considered when com-
paring the results with other reference time points
such as the date of diagnosis [9–11], start of chemo-
therapy [12] or date of study enrolment [13] to avoid
a lead time bias of up to several months (in our case,
a median of 4.4 months between diagnosis and the
day of EPP surgery). The survival times we observed
were among the best reported in the recent medical
literature [4, 7–17].
One main organ system to be considered regarding
the toxicity of radiotherapy is the remaining contralat-
eral lung. The radiotherapy, even delivered up to median
target doses of 54 Gy, was well tolerated with no higher
(4 or 5) grade toxicity to the contralateral lung. The
mean lung dose (MLD) to the contralateral lung was
(7.4 ± 2.0) Gy in all patients. Considering the rate of fatal
pneumonitis reported several years ago (6 out of 13 pa-
tients experiencing grade 5 pneumonitis, with a median
MLD of 15.2 Gy in the group of patients developing
pneumonitis [18]) and the improvements made over the
last years regarding better lung sparing, resulting in
lower lung toxicity [7], there seems to be a dose-effect
relationship for fatal pneumonitis, and an MLD around
7 Gy seems to be associated with an acceptable low risk
of higher grade lung toxicity [8]. Because of the severe
and fatal adverse effects of radiotherapy reported in
other cohorts, we think that even though we did not
observe high grade toxicity, the radiotherapy protocol
should not be intensified further, neither by enlargening
the target volume nor by escalating the dose beyond
Fig. 4 Kaplan-Meier curves separated for histology. Biphasic histology tended to be associated with worse prognosis compared to epitheloid
histology with respect to a overall survival, b locoregional control and c distant control
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54 Gy, unless new radiotherapy techniques will become
available that would allow such intensification without
increasing the dose to the organs at risk. Since all
patients received IMRT with image guidance, using in-
verse planning and collimators with narrow leafs, the
radiotherapy the patients received can be considered as
state-of-the-art even for today’s standards.
Comparing the two IMRT techniques step&shoot and
helical tomotherapy, we found no significant difference,
neither in dosimetric terms (see also [19]) nor in clinical
outcome. This notion is also supported by the finding
that none of the dosimetric variables that were statisti-
cally analyzed, including the median target dose, affected
clinical outcome such as OS, LRC and DC. The results
indicate that both techniques nowadays allow for safe
conformal hemithoracic radiotherapy with effective
sparing of organs at risk, especially the contralateral
lung. Major physical parameters for step&shoot IMRT
and helical tomotherapy were similar, explaining the
equivalence in dosimetric terms and clinical outcome:
The leaf width of the multileaf colimator (MLC) in
the isocenter plane was 5 mm for step&shoot and
6.25 mm for helical tomotherapy, both accelerators
operated at 6 MV, and both techniques included
image guidance (in-room CT for step&shoot, inte-
grated MV-CT for tomotherapy).
Further improvements in radiotherapy might be achieved
in the future in particular with respect to side effect reduc-
tion, e.g., through volumetric rotational irradiation (e.g.,
[20]) or through the use of particles. These techniques will
require also higher standards regarding plan robustness,
image guidance and plan adaptation.
One major point of discussion and controversy in clin-
ical treatment of MPM is the radicality and aggressiveness,
respectively, of the therapy concept, mainly determined by
the surgical procedure. It has been argued that EPP can
do more harm than good because of its peri- and postop-
erative morbidity and mortality [21], and that even
chemotherapy alone can result in similar survival times
[22]. However the maturity of the clinical data or the
patient numbers are often limited, or other factors make
comparisons difficult, so that there are no definite conclu-
sions possible yet. E.g., the MARS study [21] was a feasi-
bility trial in which only 19 patients actually received EPP.
In [22] the median OS of the whole cohort was 13 months
while only a subgroup of 51 out of 173 patients
reached 22 months, and the authors state that com-
parisons with other studies are difficult because sur-
gery for MPM in Scandinavia, where the study was
conducted, is performed only for very early stages
with the best performance status.
In recent years, the less radical pleurectomy/decortica-
tion (P/D) surgery procedure has frequently been pro-
posed and carried out as an alternative to EPP surgery.
In a systematic review and meta-analysis [2], it was
stated that P/D might be performed with lower morbid-
ity and mortality than EPP while resulting in comparable
long-term survival, however the authors also noted that
the comparison of both procedures has several limita-
tions and the choice for a specific therapy is still highly
individual based on the extension of the disease, the pa-
tient comorbidities and the center’s experience. The
dose-shaping potential of IMRT allows high-dose
(50 Gy) adjuvant radiotherapy even after P/D where the
ipsilateral lung has to be spared as an additional organ
at risk. First reports indicate promising clinical results:
A median OS of 24 months (from date of diagnosis, 76
pts [23]), 33 months (from date of surgery, 20 pts [24])
and 28.4 months (from date of surgery, 24 pts [25]). The
follow-up times however are still somewhat limited.
We carried out a retrospective study on a group of
MPM patients selected in the sense that they were
able to receive adjuvant radiotherapy after chemother-
apy and EPP. The decision for radiotherapy was made
after EPP individually for each patient depending on
the postoperative development, so there was no strict
intention-to-treat for trimodal therapy from the be-
ginning. EPPs were performed in several different
hospitals with some patients being referred to our in-
stitution for radiotherapy only. Therefore, an analysis
that included also the patients having received EPP
without adjuvant radiotherapy was not possible. Given
these limitations, and the fact that the disease is rela-
tively rare and no uniform treatment technique and
algorithm has been established, our results, similar to
published results by other groups, can only be com-
pared with historical data.
Clearly, randomized clinical trials would be ideal for
investigating the optimal therapy regimen for each indi-
vidual patient, but as described, they are hard to con-
duct. Therefore the main findings of the presented study
are 1) the conclusions regarding the safety of the adju-
vant radiotherapy after EPP in general, 2) the shown
equivalence of step&shoot IMRT and helical tomother-
apy and 3) the mature clinical outcome data for trimodal
therapy. We believe that the data may contribute to
some guidance what can be optimally expected from this
complicated, aggressive and technically sophisticated
regimen. Furthermore, the data can serve as a bench-
mark to be compared to in future reports on the clinical
outcome of other treatment strategies.
MPM remains a therapeutic challenge. Despite the
radical strategy, the overall survival times presented here
still show the poor prognosis of MPM patients. Both the
rate of distant metastases and local treatments need fur-
ther improvements by systemic and local options. While
surgery, radiotherapy and conventional chemotherapy will
probably remain the stage dependent mainstay of MPM
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therapy, it is likely that future concepts might integrate
novel strategies such as targeted drugs or immuno-
logical approaches based on personalized molecular
medicine data.
Conclusions
Mature clinical results of trimodal treatment for MPM
were presented. They indicate that hemithoracic radio-
therapy after EPP can be safely administered by either
step&shoot IMRT and tomotherapy. However, the opti-
mal prospective patient selection for this aggressive tri-
modal therapy approach remains unclear. This study can
serve as a benchmark for current and future therapy
concepts for MPM.
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